Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Anticancer Research|February 28, 2023
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective StudyMarina Abe, Tadahiro Shoji, Yohei Chiba, et al.
Human Cell|November 28, 2016
Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRASYohei Chiba, Seiya Sato, Hiroaki Itamochi, et al.
Japanese Journal of Clinical Oncology|January 22, 2024
A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification systemYohei Chiba, Masahiro Kagabu, Mitsumasa Osakabe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 9, 2017
Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment StrategyYohei Chiba, Seiya Sato, Hiroaki Itamochi, et al.
International Journal of Clinical Oncology|January 15, 2025
Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitorsAmi Jo, Tadahiro Shoji, Haruka Otsuka, et al.
Cancers|July 27, 2024
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian CancerSho Sato, Tadahiro Shoji, Ami Jo, et al.
International Journal of Clinical Oncology|January 22, 2026
Peripheral blood lymphocyte and eosinophil dynamics with chemotherapy and pembrolizumab in cervical cancerSho Sato, Masahiro Kagabu, Ami Jo, et al.
Cancers|May 13, 2026
Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose ReductionShunsuke Tatsuki, Tadahiro Shoji, Ami Jo, et al.
International Journal of Clinical Oncology|January 17, 2026
Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatmentEriko Takatori, Tadahiro Shoji, Ami Jo, et al.
Anticancer Research|November 29, 2025
Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective StudyEriko Takatori, Tadahiro Shoji, Ami Jo, et al.
Pageof 2